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Abstract
T cell therapy represents an emerging and promising modality for the treatment of both infectious disease and
cancer. Data from recent clinical trials have highlighted the potential for this therapeutic modality to effect potent
anti-tumor activity. Biomarkers, operationally defined as biological parameters measured from patients that provide
information about treatment impact, play a central role in the development of novel therapeutic agents. In the
absence of information about primary clinical endpoints, biomarkers can provide critical insights that allow
investigators to guide the clinical development of the candidate product. In the context of cell therapy trials, the
definition of biomarkers can be extended to include a description of parameters of the cell product that are
important for product bioactivity.
This review will focus on biomarker studies as they relate to T cell therapy trials, and more specifically: i. An
overview and description of categories and classes of biomarkers that are specifically relevant to T cell therapy
trials, and ii. Insights into future directions and challenges for the appropriate development of biomarkers to
evaluate both product bioactivity and treatment efficacy of T cell therapy trials.
Review
The central role for Biomarkers in clinical research
The ultimate objective for clinical trials is to evaluate
the safety and efficacy of novel therapeutic agents.
Although the ability to evaluate safety is in general
rather straightforward, the ability to measure clinical
efficacy is often compromised. The reasons for this are
multiple and include the variable and often long times
to progression, the fact that direct measurements on tar-
get tumors are often not possible, and also include
patient- intrinsic effects related to both patient and
tumor heterogeneity. Nonetheless, early evidence for
product efficacy and bioactivity is of critical importance
in the clinical trial process to guide the further develop-
ment of the candidate product. Well-designed biomar-
ker studies provide a primary mechanism to evaluate
product efficacy and bioactivity, and also provide funda-
mental insights into mechanistic aspects of the treat-
ment regimen.
The clinical development path for novel therapeutics
has historically followed a rather rigid and iterative
approach that has imposed certain significant limitations
on the effective development of promising therapeutics,
since the inherent rigidity of the approach does not
allow for the flexibility to either accelerate trials when
early results are particularly promising, or to modify the
trial design as information and knowledge about the
treatment impact, response and biomarker profile is
generated (see for example [1]).
Two conceptually related proposals for clinical trial
design, the adaptive [2,3] and two-stage [4] clinical trial
design paradigms, have been recently proposed to over-
come at least some of the limitations associated with
the traditional clinical development path for new thera-
peutics. Both the adaptive and two-stage clinical design
paradigms are integrally dependent on the development
and application of robust, relevant and statistically-based
biomarker studies to guide the clinical development pro-
cess; accordingly, increased implementation of these
approaches has fostered a renewed emphasis on the
development of high quality biomarker research [5-9].
Recent focus on the establishment and implementa-
tion of integrated translational research programs has
highlighted a critical role for biomarkers during preclini-
cal stages of research. In addition to guiding go-no-go
decisions to move new agents into the clinic, preclinical
biomarker studies commonly evaluate mechanistic
aspects of the product, and often serve to define both
the biomarkers to be studied and the assays to be
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employed in the clinical trial. A strong argument can
thus be made for the close integration of biomarker
development from the preclinical through the clinical
trial process.
T cell therapy clinical trials
The concept of enhancing cellular immunity through
the transfer of ex-vivo expanded T cells was pioneered
by Greenberg et al., who coined the term adoptive T
cell transfer to describe the process [10]. The first clini-
cal application of adoptive T cell transfer involved
reconstitution of cellular anti-CMV immunity in the
context of allogeneic bone marrow transplantation [11];
since then, adoptive T cell transfer has been evaluated
as a treatment modality against a number of viral dis-
eases [12-14].
Significant effort has been put forth over the past few
years to evaluate the potential to treat cancer via the
adoptive transfer of T lymphocytes, both effector lym-
phocytes (CD8 and CD4) and regulatory (Treg) cells,
manipulated ex-vivo to generate large numbers and in
some cases to enhance their activity (see for examples
[15-17]). Such efforts been enabled by enhanced under-
standing of T cell immunobiology, and facilitated by the
development of approaches to expand and manipulate T
cells ex vivo [18-20], methodologies to enable manufac-
ture under Good Manufacturing Practice (GMP)
[21-23], as well as genetic approaches to augment T cell
specificity and function [24,25]. These developments
have facilitated a broad range of clinical trials to evalu-
ate the ability of T cell therapy-based strategies to target
tumors. T cells, derived from the periphery [17,26-28],
from tumor infiltrating lymphocytes (TIL) [29-31], or
have been enriched for virus-specificities [13,32,33] to
enhance persistence have been infused into patients
after ex-vivo expansion either as bulk or antigen-specific
populations. More recently, advances in the practical
ability to genetically engineer T cells through retro- and
lenti-virus mediated transfer of DNA into primary
human T cells have opened up the opportunity to aug-
ment and re-direct anti-tumor activity through gene
transfer of tumor-antigen- specific T cell receptors
(TcR) [15,34,35] or chimeric antigen receptors (CAR) to
manifest novel anti-tumor specificities [36-38]. Even
more recently, high efficiency RNA transfer technologies
have been developed to genetically engineer T lympho-
cytes in a transient manner [20,39]. Such “biodegrad-
able” re-directed T cells afford the potential to
effectively target tumors while minimizing the potential
negative consequences associated with long-term persis-
tence of gene-modified cells. On the other hand, due to
the transient nature of the functional product, biomar-
ker studies for RNA-modified T cells are likely to be
restricted to the assessment of infusion-proximal and
acute events.
To date, essentially all T cell therapy trials have been
early stage trials with the primary objectives related to
feasibility and safety. Although dramatic results have
been observed in a number of cases, by virtue of cohort
sizes such trials have only offered tantalizing hints into
potential efficacy [15,40,41].
Biomarkers in T cell therapy trials
The vast majority of to-date clinically evaluated anti-
cancer products are in essence chemical compounds.
This holds true for bio-molecules such as antibodies,
peptide or proteins, adjuvants, small molecule agonists
and antagonists, as well as radio- and chemo-therapeutic
agents. Each of these product classes targets a physiolo-
gical process in the tumor and/or in the patient and has
a well defined half-life, but from a biological perspective
is essentially inert. Accordingly, biomarker studies for
such agents have focused on the impact of the treatment
on the target tissue(s). Examples of such efficacy bio-
markers include secreted and shed tumor products such
as PSA, PSMA, her-2-neu and many others (reviewed in
[42]), circulating tumor cells [43], the detection of mini-
mal residual disease using tumor specific genetic rear-
rangements such as Bcr-Abl [44], and more recently
tumor-specific epigenetic modifications [45].
Cell therapy trials in general and T cell trials specifi-
cally are distinguished by the fact that the product is a
biological entity whose physiological status is critical to
mediate the desired therapeutic effect; essentially, the
transferred T cells need to be both present and func-
tional for treatment to be efficacious. Consequently, T
cell therapy trials require the development and evalua-
tion of additional classes of biomarkers that describe the
biological properties of the cell product. Accordingly, a
fundamental understanding of the biomarkers that are
relevant for T cell functional competence has important
consequences for the ability to effectively evaluate T cell
bioactivity in patients.
Product Biomarkers for T cell trials
Results from both animal studies and clinical trials
have identified biological parameters that are likely to
be important for T cell bioactivity. These parameters
can broadly be described in terms of i. presence, ii.
relevant phenotypes and functional competence, iii.
systemic impact on patient biology, and iv. patient
immune responses to the infused product. A summary
of the classes of T cell biomarkers together with types
of established assays for each class as well as advan-
tages and disadvantages for each assay is presented in
Table 1.
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i. Biomarkers to evaluate T cell presence
The presence of infused T cells in patients is most com-
monly described in terms of peripheral T cell persis-
tence and homing to target tissues. For most T cell
therapy trials the total amount of T cell product infused
into patients is a fraction of the total patient T cell load,
typically no more than 0.1% of the total. However, since
most current clinical protocols that involve adoptive T
cell transfer are preceded by a lympho-depleting regi-
men, infused T cells have the potential to be found as a
significant percentage of total leukocyte counts, particu-
larly at early time-points post transfer. In addition,
because there is potential for in vivo expansion of the
infused T cells due to homeostatic and/or antigen-dri-
ven expansion, it is possible that infused cells can be
found in the reconstituted T cell compartment at num-
bers substantially higher than those infused [35,40].
The vast majority to T cell therapy trials have evalu-
ated product biomarkers in peripheral blood, which is
typically straightforward to obtain as part of routine
blood sampling during the course of treatment. A com-
pelling argument can be made, supported by recent clin-
ical data, that it also critical to evaluate the quantity and
functional quality of infused T cell products at the site
of disease [46].
Presence (persistence, homing) of infused T cell pro-
ducts has been evaluated primarily by flow cytometry
and molecular -based approaches.
Flow-cytometry-based approaches: The antigenic spe-
cificity of T cells is mediated through the a/b
heterodimer which is part of the TcR complex. Accord-
ingly, detection of specific TcR a/b pairs present on
infused cells is one approach to evaluate and quantify
infused T cell products. In most cases, this approach
requires that the frequency of specific product cells is at
least 0.2-0.5% of the total CD3+ T cell population to
accommodate technical limitations of the flow-cytome-
try platform. For products that are composed of CD8 T
cells with a defined antigenic specificity, MHC (major
histocompatibility complex) class I multimers (tetra-
mers, pentamers, dextramers) have been employed to
detect and quantify infused cells. Because class II
reagents have proven to be problematic to manufacture,
multimer-based detection approaches have been more
difficult to implement for CD4+ T cells, although recent
reports suggest progress in this area [47]. This approach
has been applied in a number of T cell therapy trials to
both detect and quantify and infused antigen-specific T
cells. As described below, this approach can be com-
bined with more detailed phenotypic and/or functional
studies to obtain more integrated data sets about the T
cell product. One caveat of this methodology is that
activation-induced down-modulation of the TcR com-
plex may result in a reduced ability to detect recently
activated cells.
A number of clinical trials are underway and/or
planned that involve the transfer of T cells gene modi-
fied to target tumors through CAR [48]; since CAR typi-
cally contain an antibody–derived ScFv (single-chain
variable fragment) component, anti-ScFv or idiotype-
Table 1 Categories and attributes of T cell biomarkers
Category Platforms Assay Advantages Disadvantages
Presence Flow cytometry Surface marker detection Individual cells detected Sample intensive
Low sensitivity
Specific detection reagent
PCR Transgene-specific amplification High sensitivity Bulk analysis
Deep sequencing Detection of specific TcR clonotypes Extremely high sensitivity Technology intensive
Phenotype/
Function







Bioactivity Flow Cytometry Surface and intracellular marker
detection
Individual cells detected Low sensitivity
Sample intensive
















Flow cytometry Cellular and humoral immune
responses
Individual responses can be
characterized
Low sensitivity
Often requires in vitro
expansion
ELISA Humoral immune responses High sensitivity
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specific antibody reagents that recognize the CAR could
be used as reagents to detect and enumerate antigen-
specific T cells; a successful application of this concept
to detect, quantify and study the phenotype of persisting
CAR-modified T cells by multi-parameteric flow cyto-
metry has been recently reported [40].
Another flow-cytometry-based approach to identify
and track T cell products takes advantage of the wide
availability of antibodies that recognize the variable seg-
ment of the TcRb chain (Vb). A total of 65 Vb segments
in the TcRb locus have been identified that can be
grouped into 25 Vb families with each family represent-
ing roughly 0.2-5% of the total T cell population [49].
This approach is dependent on a monoclonal or at most
oligoclonal T cell product, and a relatively high level
persistence of infused cells (> 5% of total CD3+ cells)
because of the normal distribution of T cells from each
Vb family in the non-modified T cell repertoire. Since
the Vb antibody reagents detect both endogenous and
infused T cells with equal efficiency, definitive quantifi-
cation of infused cells using this approach is not possi-
ble. This approach has been used in a number of
clinical trials to evaluate T cell persistence (see for
example [35,50,51]. As above, this approach is suscepti-
ble to the consequences of activation-induced receptor
down-modulation.
Finally, Wang et al have recently described the devel-
opment of a truncated EGFR polypeptide devoid of all
known ligand-binding and signaling domains that can
be co-introduced into human T cells and serve both a
selection marker as well as a cell -surface tracking mar-
ker for adoptively transferred cells [52]. While such pro-
mising approaches offer the potential to bypass
limitations associated with down-modulation, they do
open up the possibility for immune rejection responses
that target unique peptide epitopes from the modified
polypeptides.
A different approach to evaluate T cell persistence has
involved the use of quantitative PCR (Q-PCR). This
approach is possible if the T cell product has been
genetically engineered to contain transgenes, such as
TcR, CAR, or selectable markers such as neomycin
phosphotransferase and HyTK; in principle, if sufficient
sequence information is available, this approach can also
be utilized with primer/probe pairs specific for the Vb
sequence of the infused products [53]. This methodol-
ogy has been applied in a number of clinical studies
[36,40,41,51,54,55], and is considerably more sensitive
than flow cytometry-based approaches, with an ability to
detect modified cells at frequencies as low as 0.01% of
total T cells. Significant limitations of this approach
include the facts that data are generated from a bulk
population of cells, that this approach is not readily
amenable to dissecting in more detail the phenotype
and function of the persisting T cell population, as well
as the fact that this approach does not provide informa-
tion about the expression status and function of the
evaluated transgene. Notably, for biodegradable RNA-
based T cell products Q-RT-PCR rather than Q-PCR
must be utilized to track and quantify infused cells.
Novel technologies that enable high-throughput and
deep sequencing of TcR variable and CDR3 domains
from bulk PBMC [56,57] afford the opportunity to com-
prehensively evaluate the T cell diversity of infusion
products and track directly ex-vivo the expansion, per-
sistence and homing of infused cells with very high
sensitivity.
ii. Biomarkers to measure biologically relevant phenotypes
and functions of T cells
Over the past few years technical advancements in poly-
chromatic flow-cytometry have enabled a substantially
more detailed phenotypic and functional evaluation of T
cell products. Flow cytometry analyses that simulta-
neously evaluate 12-marker are routinely performed in
research laboratories while analyses that involve up to
17 markers can be performed by specialized laboratories
[58-60]. Such analyses are dependent on the ability to
identify the infused T cell product using multimers,
anti-Vb, or anti-T cell surface receptor antibodies as
described above, and typically employ combinations of
antibodies specific for surface markers that interrogate
T cell differentiation, activation, and functional status
and intracellular markers that reveal T cell functional
activity. New technologies such as inductively-coupled
mass spectrometry (ICP-MS) that can detect and quan-
tify heavy-metals conjugated to individual antibodies
offer the potential to simultaneously query for co-
expression of large numbers of markers unencumbered
by limitations associated with spectral overlap and dif-
ferential emission of fluorescent molecules [61,62].
Recent data from both animal models and clinical
trials have provided important insights about T cell phe-
notypes that may causally correlate with treatment effi-
cacy: Data generated principally from the surgery
branch at the NCI using adoptive transfer of TIL have
suggested that treatment efficacy is related to the persis-
tence of T cells that are or can convert in-vivo to mem-
ory cells [54,63]; such cells are capable of long term
persistence, a property that may well be required for
ultimate efficacy of T cell therapy. These results have
been more systematically evaluated and confirmed in
primate models [64], and a number of clinical trials are
being planned at multiple institutions that involve the
specific transfer of memory cell populations into
patients.
A large variety of surface markers have been described
in the literature as potential biomarkers for T cell differ-
entiation status related to functional competence.
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Common markers for such analyses include T cell dif-
ferentiation markers such CD45 RA or RO, CD62L,
CCR7, CD27, CD28, combined with T cell activation
markers such as CD25, CD127, CD57, and CD137
[65,66]. Although there is some uncertainty about what
surface markers best define T cell differentiation state,
commonly accepted phenotypic markers for the differ-
ent subsets include the following (differentiation status
phenotypes in [brackets]: CD45RO/CCR7/CD27/CD57:
[naïve: -/+/+/-]; [effector memory: +/-/-/-]; [effector:
-/-/+/+ and -/-/-/+]; [central memory +/+/+/-, +/-/+/-,
+/-/+/+] [66].
Data from clinical trials that have evaluated the abil-
ity of vaccines to elicit a protective immune response
in the infectious disease field have revealed that pro-
tective responses are also associated with the quality of
the T cell response and the presence of T cells that
simultaneously express multiple effector functions,
defined as polyfunctional T cells [67-69]. Functional
markers often evaluated include IL-2, TNF-a, IFN-g,
MIP1b and the de-granulation marker CD107, and
protective responses are associated with polyfunctional
T cells (both CD4 and CD8) which express high levels
for each of the above factors. In addition, it is relevant
to evaluate surface molecules such as CD25/CD127
associated with a suppressor T cell phenotype in CD4+
T cells (CD25++/CD127-) [70], as well as PD-1, BTLA,
and TIM-3 which are associated with a state of T cell
inhibition. More recent studies have revealed that cyto-
toxic T cells which express high levels of perforin,
granzyme-B and the transcription factor T-bet are
associated with protective responses in viral diseases,
supporting the position that one or more of these
functional markers be included in biomarker panels
[71-73]. Efforts are ongoing to optimize and validate
strategies that seek to evaluate memory phenotype and
polyfunctionality [74]. However, embracing the to-date
defined markers as defining the signature of a biologi-
cally relevant polyfunctional cell must be done with
significant caution since it is extremely unlikely that
the full extent of the optimal biological phenotype has
been defined [75].
Studies from the NCI have revealed that telomere
length was the one biomarker that consistently corre-
lated with persistence of infused T cells [51], reflecting
at least in part the concept that “younger” less differen-
tiated cells may be more efficacious in vivo. More
recently, Turtle et al. have demonstrated a surface mar-
ker phenotype for a distinct subset of T cells with self-
renewing capabilities that may play important roles in
the establishment of T cell memory subsets [76]; obser-
vations such as these are likely to also play key roles to
guide the development of the next generation of bio-
markers to evaluate in T cell therapy trials.
Multi-parametric analyses that combine the evaluation
of surface and activation markers with effector function
markers such as CD107a/b, perforin and granzyme,
intracellular detection of effector cytokines such as IL-2,
IFN-g, TNF-a, IL-4, MIP-a, MIP1B, and concomitantly
the phosphorylation status of intracellular signaling
molecules important for T cell function [77,78] afford
the potential, still largely untapped, to evaluate directly
ex-vivo T cell functional competence and identify treat-
ment and outcome relevant biomarkers.
As discussed above, recently described novel high-
throughput and deep sequencing technologies afford the
opportunity to evaluate in a systematic and essentially
comprehensive manner the T cell repertoire diversity
directly ex-vivo [56,57]. Such approaches, combined
with tools such as those described above to enrich for
defined T cell subsets and specificities, have the poten-
tial to revolutionize the ability for insights into the bio-
marker signature(s) associated with clinically relevant T
cell bioactivity.
Finally, important insights about the relevant biomar-
kers to evaluate with regard to T cell phenotypes and
function can be derived from the characterization and
release testing associated with product manufacture. In
particular, well defined and robust assays for product
identity and potency that measure relevant functional
parameters for the products can provide valuable infor-
mation about the properties of the cell product, as well
as help establish and qualify the assays that will be used
on the clinical samples.
iii. Biomarkers to evaluate T cell bioactivity
Insights about product bioactivity can often be obtained
by evaluating the impact of the treatment on patient
biology. A classic example of this is the delayed-type
hypersensitivity (DTH) reaction observed at the site of
injection, which is associated with an injection-mediated
inflammatory reaction. Autoimmune vitiligo associated
with the destruction of normal melanocytes has been
reported to be associated with anti-tumor activity fol-
lowing melanoma T cell immunotherapy [79]. More
recently significant off -tumor-target antigen-specific
autoimmunity was observed when T cells specific for
antigens expressed by normal tissues were transferred to
patients [80-82]. These unfortunate results have revealed
at least some of the pitfalls associated with the potency
of T cell therapy-based clinical strategies, and under-
score the urgent need to identify and develop early bio-
marker signatures to track these non-desired
consequences of T cell therapy-based strategies. Cyto-
kine analyses of serum samples obtained pre- and post-
treatment appear to be particularly useful in this regard:
such analyses have revealed evidence for a pre-infusion
elevated cytokine milieu (elevation of IL-2, IL-7, IL-15,
and IL-12) in one case [82], and evidence for severe
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cytokine storm post infusion T cell infusion in another
case; cytokine storm was associated with elevated levels
of the factors IFN-g, GM-CSF, TNF-a, IL-6, and IL-10
[81]. These observations have prompted a movement for
real-time assessment of systemic levels for the above
cytokines in patients during treatment, particularly
when cytokine-storm related symptoms are observed.
Such real-time cytokine assessment was recently applied
and used to support the documentation of delayed (22
days post T cell infusion) tumor lysis syndrome in a
CLL patient with advanced treatment-refractory disease
following infusion of T cells modified to express a CAR
that targeted CD19. The delayed tumor lysis syndrome
in this patient was diagnosed on the basis of significant
elevations in uric acid, phosphorus, and lactate dehydro-
genase as well as evidence of acute kidney injury with
elevated creatinine levels, and was paralleled by robust
in vivo expansion of CAR-modified cells and dramatic
but transient increases in systemic levels for a number
of pro-inflammatory cytokines and chemokines and a
rapid and robust clinical response [41]. A related recent
report describes the use of multiplex bead array technol-
ogy to monitor in a systematic manner the modulation
of a collection of 30 cytokines, chemokines, and growth
factors in peripheral blood and marrow samples from
CLL patients treated with CD19 CAR modified T cells;
these studies showed transient modulation for a number
of factors that coincided with peak T cell proliferation
and activity, followed by return to baseline values
despite long-term persistence and functionality of
infused modified cells [40].
The development of new systems biology-based plat-
forms has provided the opportunity to query the impact
of T cell bioactivity on patient biology at a broader
level. Such platforms, which have not yet been exten-
sively applied to T cell therapy trials, include molecular
array-[83,84] and proteomics- [85,86] based analyses, as
well as high throughput multiplex-bead array based
assays to measure changes in cytokine, chemokine, and
other immune factors in patients post-T cell infusion.
The systematic application of these and other systems-
biology-based platforms has the potential to provide
fundamental and unprecedented insights into molecular,
secreted and functional biomarkers that correlate with T
cell bioactivity and effective anti-tumor immunity.
iv. Biomarkers to evaluate patient immune responses to the
infused T cells
In essentially all to-date clinical trials, T cell products
are manipulated ex-vivo prior to infusion into
patients. The primary objective of such manipulations
is to enhance the potency of the product by increasing
T cell numbers through culture and/or to endow T
cells with novel/enhanced anti-tumor functionalities.
In the context of autologous T cell transfer, many of
these manipulations also have the potential to make
the T cell immunogenic following transfer. The move
away from xenobiotic sera and toward using serum-
free formulations for T cell expansion cultures has
minimized a major source of potential immunogeni-
city attributable to the manufacturing process. Two
major potential sources of immunogenicity are related
to the genetic engineering required to endow T cells
with enhanced anti-tumor functionality. The first
source of potential immunogenicity is the existence of
non-self translated open reading frames expressed by
the vector. Such open reading frames can be inten-
tional, for example to express non- human gene pro-
ducts such as neomycin phosphotransferase which
allow selection for gene-modified cells and the HyTK
fusion protein which allows for both selection of mod-
ified cells and, by virtue of the thymidine kinase (TK)
gene product, in-vivo selection against infused cells.
Anti-transgene cellular immune responses to such
selectable gene products which mediate T cell rejec-
tion have been demonstrated in a number of cases
using both in-vitro culture and expansion [87] as well
as directly ex vivo using a combination of Vb spectra-
typing and CD107 degranulation [55]. The second
source of potential immunogenicity is a result of the
use of murine antibody scFv determinants and the
creation of unique junctional fragments in the design
of chimeric antigen receptors; recent reports describes
the generation of both humoral and in one case cellu-
lar immune responses that target CAR sequence
determinants as well the generation of cellular
immune responses against what were presumably epi-
topes derived from the retrovirus vector backbone;
detection of these responses was associated with dis-
appearance of infused cells from the peripheral circu-
lation [88,89]. Since the generation of anti-infused T
cell immunity has profound implications for T cell
persistence, such analyses ought to be considered an
essential component of T cell biomarker studies.
Conclusions
The significant potential of T cell immunotherapy as an
effective approach to target cancer is beginning to be
realized in a number of clinical settings. As discussed
above, a wide variety of biomarkers have been developed
and are available to evaluate T cell bioactivity. Since it is
unlikely that clinical efficacy of T cell immunotherapy
based approaches will be causally associated with a sin-
gle biomarker, a major challenge for the field will be to
establish the infrastructure to support biomarker ana-
lyses that are as comprehensive and broad as possible,
and driven by principles of quality [9]. Development of
this infrastructure needs to specifically be supported by
the following elements:
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A. The development and integration into T cell bio-
marker studies of assay platforms that are more sensitive
and capable of higher complexity analyses. In this
regard, array and other high throughput analysis based
platforms that can evaluate large panels of nucleic acid
or protein biomarkers are likely to be particularly useful.
B. The establishment of quality infrastructure and
operations in laboratories that perform T cell biomarker
analyses to facilitate the generation and collection of
robust data sets that can be applied to generate statisti-
cally meaningful conclusions from relatively small
cohorts and samples sets.
C. The development of algorithms and programs that
allow for the multi-factorial and/or Boolean analyses of
the data, as described elegantly by a number of groups
[59,60,90,91], that will enable a more systems biology-
based analysis of biomarker data sets generated in T cell
therapy trials.
D. As recommended by the minimum reporting
guidelines consortium(MIBBI) [92], The development
and implementation of appropriate annotation and sto-
rage of data in repositories that can be openly accessed
by the research community to facilitate more detailed
and cross-study prospective or retrospective analyses of
data. In particular for T cell therapy-based trials, the
MIATA (Minimum Information About T-cell Assays)
initiative has been established to specifically facilitate
the identification of the relevant parameters important
to document and report about T cell assays [93].
Establishment and implementation of the above ele-
ments may ultimately allow for the identification of pro-
duct biomarker combinations that causally correlate
with efficacy and therefore can be developed as surro-
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